Tokyo, Japan

Kazuyoshi Sagara

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Mitsubishi Tanabe Pharma Corporation. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuyoshi Sagara. Retrieved from https://idiyas.com/inventor/kazuyoshi-sagara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuyoshi Sagara: Innovator in Pharmaceutical Compositions

Introduction

Kazuyoshi Sagara is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that control pH ranges and release rates.

Latest Patents

Sagara holds a patent for "Compositions controlling pH range of release and/or release rate." This invention provides a composition that includes a thienotriazolodiazepine compound and at least one ingredient selected from a group of polymers and surfactants. The innovation aims to enhance the effectiveness of pharmaceutical formulations.

Career Highlights

Kazuyoshi Sagara is associated with Mitsubishi Tanabe Pharma Corporation, where he has been instrumental in advancing pharmaceutical technologies. His work focuses on improving drug delivery systems and optimizing therapeutic outcomes.

Collaborations

Sagara has collaborated with notable colleagues, including Hirofumi Samemoto and Hirotsugu Komatsu. These partnerships have fostered innovation and contributed to the success of various projects within the pharmaceutical industry.

Conclusion

Kazuyoshi Sagara's contributions to pharmaceutical compositions highlight his role as an innovator in the field. His patent reflects a commitment to enhancing drug delivery systems, which can significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…